Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours-Reference-Cited by-同舟云学术

Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

Published:2013-05 Issue:8 Volume:49 Page:1815-1824
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Soria Jean-Charles,Baselga José,Hanna Nasser,Laurie Scott A.,Bahleda Rastislav,Felip Enriqueta,Calvo Emiliano,Armand Jean-Pierre,Shepherd Frances A.,Harbison Christopher T.,Berman David,Park Jong-Soon,Zhang Steven,Vakkalagadda Blisse,Kurland John F.,Pathak Ashutosh K.,Herbst Roy S.

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference42 articles.

1. ERBB receptors and cancer: the complexity of targeted inhibitors;Hynes;Nat Rev Cancer,2005

2. Role of vascular endothelial growth factor in the regulation of angiogenesis;Ferrara;Kidney Int,1999

3. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

4. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;N Engl J Med,2007

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy;Chemical Biology & Drug Design;2024-05

2. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and In Vitro Study;Journal of Chemical Information and Modeling;2021-10-20

3. Therapeutic Aspects of Heat Shock Proteins in Glioma: Cementing the Crevasses Between Bench and Bedside;Heat Shock Proteins in Neuroscience;2019

4. Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer;Current Cancer Drug Targets;2018-09-14

5. Programmed death receptor Ligand 1 expression in eyelid sebaceous carcinoma: a consecutive case series of 41 patients;Acta Ophthalmologica;2018-06-04